Get started
Author

Alan Rong

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
2013 · Jean-Yves Douillard, Kelly S. Oliner, et al. · New England Journal of Medicine · 2,257
PDF
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
2010 · Marc Peeters, Timothy Jay Price, et al. · Journal of Clinical Oncology · 1,006
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
2015 · J. Randolph Hecht, Jean-Yves Douillard, et al. · Cancer Treatment Reviews · 60
Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy
2015 · Tu Xu, Yixin Fang, et al. · BMC Medical Research Methodology · 54
PDF
Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
2013 · Roger Sidhu, Alan Rong, et al. · Clinical Cancer Research · 53
Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).
2013 · Kelly S. Oliner, Jean-Yves Douillard, et al. · Journal of Clinical Oncology · 52
14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
2009 · M. Peeters, T. Price, et al. · European Journal of Cancer Supplements · 31
Weighted log‐rank test for time‐to‐event data in immunotherapy trials with random delayed treatment effect and cure rate
2018 · Shufang Liu, Chenghao Chu, et al. · Pharmaceutical Statistics · 27
Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer
2010 · Michel Ducreux, Timothy Price, et al. · Europe PMC (PubMed Central) · 23
TITE‐gBOIN : Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades
2021 · Kentaro Takeda, Qing Xia, et al. · Pharmaceutical Statistics · 19
Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers
2021 · Kentaro Takeda, Shufang Liu, et al. · Statistics in Medicine · 16
Biomarker threshold adaptive designs for survival endpoints
2018 · Guoqing Diao, Jun Dong, et al. · Journal of Biopharmaceutical Statistics · 16
Estimation of delay time in survival data with delayed treatment effect
2018 · Wei Li, Sophie Yu-Pu Chen, et al. · Journal of Biopharmaceutical Statistics · 9
An adaptive biomarker basket design in phase II oncology trials
2022 · Shufang Liu, Kentaro Takeda, et al. · Pharmaceutical Statistics · 7
Study design of single‐arm phase II immunotherapy trials with long‐term survivors and random delayed treatment effect
2020 · Chenghao Chu, Shufang Liu, et al. · Pharmaceutical Statistics · 6
Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects
2017 · Guoqing Diao, Donglin Zeng, et al. · Journal of Biopharmaceutical Statistics · 5
Pattern mixture models for clinical validation of biomarkers in the presence of missing data
2017 · Fei Gao, Jun Dong, et al. · Statistics in Medicine · 4
Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone in the PRIME trial.
2015 · Jianmin Wang, Jun Dong, et al. · Journal of Clinical Oncology · 3
Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC)
2013 · Kelly Oliner, Jean-Yves Douillard, et al. · Annals of Oncology · 3
A basket trial design based on constrained hierarchical Bayesian model for latent subgroups
2024 · Kentaro Takeda, Atsuki Hashimoto, et al. · Journal of Biopharmaceutical Statistics · 2
Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs
2023 · Ran Li, Kentaro Takeda, et al. · Therapeutic Innovation & Regulatory Science · 2
The PRIME trial: Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone.
2015 · Jianmin Wang, Jun Dong, et al. · Journal of Clinical Oncology · 2
Chromothripsis in Uterine Leiomyomas
2013 · Jean‐Yves Douillard, Alan Rong, et al. · 2
Palifermin reduces severe oral mucositis (OM), improves patient quality of life, and reduces health resource use in patients with hematologic malignancies receiving high-dose chemotherapy (HDCT) and total body irradiation (TBI) with autologous peripheral blood stem cell (PBSC) support: results from a phase III trial
2004 · W. Bensinger, D. Weisdorf, et al. · Transplantation and Cellular Therapy · 2
PDF
MC13-0021 Impact of post-protocol anti-epidermal growth factor receptor therapy on survival in wild-type KRAS/NRAS metastatic colorectal cancer: Data from the PRIME study
2013 · M. Peeters, J.Y. Douillard, et al. · European Journal of Cancer · 1
Works count: 46
Citation count: 3,665
H-index: 12
I10-index: 12
Year
Topic
Type